In the last trading session, 3.91 million Cue Biopharma Inc (NASDAQ:CUE) shares changed hands as the company’s beta touched 1.94. With the company’s per share price at $0.68 changed hands at $0.23 or 49.61% during last session, the market valuation stood at $33.05M. CUE’s last price was a discount, traded about -377.94% off its 52-week high of $3.25. The share price had its 52-week low at $0.45, which suggests the last value was 33.82% up since then. When we look at Cue Biopharma Inc’s average trading volume, we note the 10-day average is 0.58 million shares, with the 3-month average coming to 431.90K.
Analysts gave the Cue Biopharma Inc (CUE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CUE as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Cue Biopharma Inc’s EPS for the current quarter is expected to be -0.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cue Biopharma Inc (NASDAQ:CUE) trade information
Instantly CUE was in green as seen at the end of in last trading. With action 29.66%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -74.27%, with the 5-day performance at 29.66% in the green. However, in the 30-day time frame, Cue Biopharma Inc (NASDAQ:CUE) is -2.94% down. Looking at the short shares, we see there were 3.56 million shares sold at short interest cover period of 16.24 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 88.67% from its current market value. According to analyst projections, CUE’s forecast low is 2 with 7 as the target high. To hit the forecast high, the stock’s price needs a -929.41% plunge from its current level, while the stock would need to soar -194.12% for it to hit the projected low.
Cue Biopharma Inc (CUE) estimates and forecasts
Year-over-year growth is forecast to reach 102.70% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 1.52M. 4 analysts are of the opinion that Cue Biopharma Inc’s revenue for the current quarter will be 5.23M. The company’s revenue for the corresponding quarters a year ago was 1.13M and 1.82M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 34.50%. The estimates for the next quarter sales put growth at 187.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.55%. The 2024 estimates are for Cue Biopharma Inc earnings to increase by 37.16%.
CUE Dividends
Cue Biopharma Inc is expected to release its next quarterly earnings report on 2024-Nov-07.
Cue Biopharma Inc (NASDAQ:CUE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.68% of Cue Biopharma Inc shares while 28.55% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 28.74%. There are 28.55% institutions holding the Cue Biopharma Inc stock share, with BLEICHROEDER LP the top institutional holder. As of 2024-06-30, the company held 5.7849% of the shares, roughly 2.86 million CUE shares worth $3.55 million.
SLATE PATH CAPITAL LP holds the second largest percentage of outstanding shares, with 4.8567% or 2.4 million shares worth $2.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . With 1.35 shares estimated at $0.92 million under it, the former controlled 2.77% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.23% of the shares, roughly 597.57 shares worth around $0.41 million.
